Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates despite revenue from its weight loss drugs Mounjaro and Zepbound falling short of expectations.
Revenue surged 45% year-over-year to $13.53 billion, slightly below the $15.37 billion expected by Wall Street analysts.
Mounjaro achieved revenue of $3.53 billion for Q4, up 60% year-over-year but short of the $3.62 billion expected by analysts.
Zepbound sales were $1.91 billion, below the $1.98 billion consensus.
Eli Lilly noted it saw volume growth for both drugs, however lower realized prices were driven by Mounjaro.
The drugmaker’s fourth quarter earnings per share of $5.32 topped estimates of $4.95.
The company also issued in-line guidance for 2025, expecting revenue in the range of $58 billion to $61 billion and EPS between $22.50 and $24.
“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” Eli Lilly CEO David Ricks said in a statement.
Shares of Eli Lilly traded 2.2% higher at about $861 shortly after the opening bell in New York.